---
title: "Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002589.SZ.md"
symbol: "002589.SZ"
name: "Realcan Pharmaceutical Group Co., Ltd."
industry: "Health Care Distributors"
datetime: "2026-05-20T01:32:17.674Z"
locales:
  - [en](https://longbridge.com/en/quote/002589.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002589.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002589.SZ.md)
---

# Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)

## Company Overview

Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materials, herbal medicine, and patent medicine.

| Item | Detail |
|------|--------|
| Industry | Health Care Distributors |
| Exchange | CN Market |
| Website | [www.realcan.cn](https://www.realcan.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: D (0.67)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 21 / 23 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.94% |  |
| Net Profit YoY | 55.80% |  |
| P/B Ratio | 0.85 |  |
| Dividend Ratio | 0.13% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4539886280.50 |  |
| Revenue | 7239770806.90 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.27% | D |
| Profit Margin | 0.20% | D |
| Gross Margin | 12.78% | D |
| Revenue YoY | -5.94% | D |
| Net Profit YoY | 55.80% | B |
| Total Assets YoY | -3.08% | D |
| Net Assets YoY | -4.29% | D |
| Cash Flow Margin | -188.11% | E |
| OCF YoY | -5.94% | D |
| Turnover | 0.46 | C |
| Gearing Ratio | 64.98% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Realcan Pharmaceutical Group Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-5.94%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "55.80%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.85",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.13%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4539886280.50",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "7239770806.90",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.27%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.20%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "12.78%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "-5.94%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "55.80%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.08%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-4.29%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-188.11%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-5.94%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.46",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "64.98%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 319.71 | 20/23 | 361.82 | 243.84 | 229.27 |
| PB | 0.86 | 5/23 | 0.94 | 0.85 | 0.81 |
| PS (TTM) | 0.63 | 17/23 | 0.69 | 0.62 | 0.58 |
| Dividend Yield | 0.13% | 22/23 | 0.37% | 0.24% | 0.12% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | HUADONG MEDICINE (000963.SZ) | B | C | A | B | C | B |
| 02 | SINOPHARM(CNCM LTD) (600511.SH) | C | C | A | C | C | B |
| 03 | TIBET PHARMA (600211.SH) | A | C | C | B | C | B |
| 04 | Shanghai Pharma (601607.SH) | C | C | A | D | C | C |
| 05 | GYBYS (600332.SH) | C | C | A | C | C | C |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002589.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002589.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002589.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002589.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**